openPR Logo
Press release

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017 by P&S Market Research

04-19-2017 02:45 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline

The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates, of which eight drug candidates are in Phase III stage, 10 drug candidates are in Phase II stage, nine drug candidates Phase I stage, eight in Pre-Clinical stage and two drug candidates are in Discovery stage.

Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.

Explore Report Description at: www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis

Pipeline Insights

The pipeline for PI3K inhibitors was analyzed based on route of administration, molecule type and phase of drugs. Based on route of administration, around 57.0% active drug candidates are being developed to be administered by oral route, 8.0% by intravenous route and 5.0% to be administered by other routes, including inhalation and intravitreally or subconjunctivally. Most of the drug candidates are being developed to be administered by oral route, due to high patient compliance. Route of administration of around 30.0% active PI3K drug candidates pipeline is not disclosed.

Several companies are targeting PI3K pathways for the treatment of cancer and various other diseases in different phases. The pharmaceutical companies engaged in manufacturing of PI3K inhibitors include, but are not limited to, Novartis Pharmaceuticals, F. Hoffmann-La Roche AG, Verastem, Inc., Bayer AG, GlaxoSmithKline plc, SignalRX Pharmaceuticals Inc., Eli Lilly and Company and PIQUR Therapeutics AG. Novartis AG is developing Buparlisib and Alpelisib, which are Phase III drug candidates.

Explore Report Sample at: www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis/report-sample

Positive clinical results from drug candidates targeting PI3K

In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687). The full analysis set comprised of 142 patients, of which 141 patients had iNHL. At the time of analysis, median duration of treatment was 22 weeks and 46 patients remained on treatment. In the FL subset of CHRONOS-1 (n=104), copanlisib treatment resulted in an ORR of 58.7%, including a CR of 14.4% and a median median duration of response of more than 52 weeks, or 370 days (range 0-687), with safety being generally consistent. The most common treatment-related adverse events were transient hyperglycemia (all grades: 49%/Grade ≥3: 40%), which did not show severity above Grade 4, and hypertension (all grades: 29%/Grade ≥3: 23%), which did not show severity above Grade 3.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Major companies collaborate for the development of PI3K inhibitors pipeline

The research found that different companies engaged in manufacturing of PI3K inhibitors are collaborating. One of the collaborations occurred in November 2016 between Verastem, Inc. and Infinity Pharmaceuticals, Inc. Under the terms of the agreement, Verastem, Inc. licensed all exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. Verastem paid Infinity Pharmaceuticals, Inc. up to $28.0 million in milestones, with positive data from DUO, a Phase III, randomized monotherapy study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia, triggering the first milestone payment, and royalties on net sales.

Some of the key players developing PI3K inhibitors pipeline include Novartis Pharmaceuticals, F. Hoffmann-La Roche AG, SignalRX Pharmaceuticals Inc., Verastem, Inc., Bayer AG, GlaxoSmithKline plc, Eli Lilly and Company and Takeda Pharmaceutical Limited.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017 by P&S Market Research here

News-ID: 507560 • Views: 334

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for PI3K

Deep Research: PI3K Signaling Pathway Analysis: A Shifting Marketed And Pipeline …
Latest report, PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets, provides a comprehensive assessment of the marketed and pipeline products acting on various components of the phosphoinositide 3-kinase (PI3K) signaling network. Get Free Sample PDF (Including Full TOC, Tables And Figures) of Market @ https://www.researchmoz.us/enquiry.php?type=S&repid=2047692 The PI3K pathway is a critical signal transduction pathway and plays important roles in the
PI3K inhibitors Market : Growth Opportunity and Industry Revenue Analysis By Maj …
Global PI3K inhibitors Market Size, Status and Forecast 2020 Our new sample is updated which correspond in new report showing impact of COVID-19 on Industry The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porter’s five techniques for analyzing the PI3K inhibitors Market; it also offers the examination of the global market. To make the report more potent and easy to understand,
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation Analysis and Glo …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug
PI3K Signaling Pathway Market Growth with Worldwide Industry Analysis Up to 2025
A new research document with title 'PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like United States, Asia-Pacific, China, Japan, India, Asia and important players/vendors.The report will help user gain market insights, future trends and growth prospects for forecast period
Phosphatidylinositol 3-Kinase Inhibitors - Pipeline, Clinical Trials and Key Pla …
The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development. Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is
Major companies collaborate for the development of PI3K inhibitors pipeline
The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development. Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis/report-sample Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival,